News
-
-
-
-
-
-
-
PRESS RELEASE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences, Inc. has entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia to advance the development of its systemic DNase program, targeting neutrophil extracellular traps involved in cancer progression. The company believes that the data generated by its research and development collaborations are crucial for unlocking the potential of its DNase technology and driving a clinical path for its lead solid tumor indications. The agreement with UVA provides a significant addition to Xenetic's development capabilities and resources, accelerating development timelines. Dr. Allan Tsung, an internationally recognized surgical oncologist and scientist, will oversee the research conducted under the agreement. Xenetic is working towards its planned first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy. For more information, visit Xenetic Biosciences' website at www.xeneticbio.com. -
-
-
Revolutionizing Fire Camps: NUE's Sustainable Power Solutions Shine at USDA Technology & Development Center
-
Save A Train Continues to Innovate with Rail Enrichment
-
Cameron Ashley Building Products Opens Third Location in the Badger State
-
Event Tickets Center is Named Official Secondary Ticketing Reseller Partner for Most Valuable Promotions and the Historic Jake Paul vs. Mike Tyson Fight
-
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect
-
Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares
-
secunet Security Networks AG successfully holds Annual General Meeting – Broad approval for all proposed resolutions
-
TUI AG: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
-
Fuller, Smith & Turner PLC: Transaction in own shares
-
AngloGold Ashanti US$9.0m (A$13.5m) Gold Farm-in Agreement
-
2024 Annual General Meeting: approval of all resolutions submitted to the Meeting
-
PR – ICADE – Success of the cash tender offer for a total amount of €350 million
-
AMOEBA: ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 27 JUNE 2024 - Availability of preliminary documents
-
Availability of preparatory documents for the annual general meeting of June 13, 2024
-
Safran’s 2024 Annual General Meeting